Dementia trials are slow and expensive compared to other disease conditions. Despite the high number of persons developing Alzheimer’s disease each year, on average a clinical trial site only recruits 8-10 participants per year for a particular trial. Among those referred to a trial, most fail the strict inclusion/exclusion criteria.
Access Free Diagnostic Assessment
By referring your patient to the Australian Dementia Network (ADNeT) Screening for Trials program, your patient will undergo a comprehensive free diagnostic assessment using techniques that are not routinely available, such as PET amyloid and tau brain scans. With these methods, Alzheimer’s disease can be detected up to 15 years before symptoms become evident (“preclinical AD”).
Results from the assessments are provided to the referring doctor, along with tailored trial recommendations.
We currently have screening sites operating in Melbourne, Adelaide, Sydney, Newcastle, Brisbane, and Perth.
Before referring a patient to the ADNeT Screening for Trials program, please ensure the patient meets all of the following conditions:
- Probable MCI or mild AD
- Aged 50 – 80 years
- Reliable study partner/informant available
- Minimum MMSE score ≥ 20
- No serious unstable comorbid conditions
Refer a Patient Now
You can refer your patient to the ADNeT Screening for Trials program by:
- getting in touch with your local screening locations (click here for more information), or
- completing the below electronic form below.